Treatment of refractory chronic GVHD with rituximab: A GITMO study

F. Zaja, A. Bacigalupo, F. Patriarca, M. Stanzani, M. T. Van Lint, C. Filì, R. Scimè, G. Milone, M. Falda, C. Vener, D. Laszlo, P. E. Alessandrino, F. Narni, S. Sica, A. Olivieri, A. Sperotto, A. Bosi, F. Bonifazi, R. Fanin

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to ≥6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes 6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n = 3), disease relapse (n = 1), infection (n = 3), sudden death (n = 1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.

Original languageEnglish
Pages (from-to)273-277
Number of pages5
JournalBone Marrow Transplantation
Volume40
Issue number3
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Graft vs Host Disease
Survival
Pure Red-Cell Aplasia
Therapeutics
Myasthenia Gravis
Vagina
Sudden Death
Mouth
Disease Progression
Cause of Death
Joints
Monoclonal Antibodies
Rituximab
Recurrence
Lung
Skin
Liver
Infection

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Zaja, F., Bacigalupo, A., Patriarca, F., Stanzani, M., Van Lint, M. T., Filì, C., ... Fanin, R. (2007). Treatment of refractory chronic GVHD with rituximab: A GITMO study. Bone Marrow Transplantation, 40(3), 273-277. https://doi.org/10.1038/sj.bmt.1705725

Treatment of refractory chronic GVHD with rituximab : A GITMO study. / Zaja, F.; Bacigalupo, A.; Patriarca, F.; Stanzani, M.; Van Lint, M. T.; Filì, C.; Scimè, R.; Milone, G.; Falda, M.; Vener, C.; Laszlo, D.; Alessandrino, P. E.; Narni, F.; Sica, S.; Olivieri, A.; Sperotto, A.; Bosi, A.; Bonifazi, F.; Fanin, R.

In: Bone Marrow Transplantation, Vol. 40, No. 3, 08.2007, p. 273-277.

Research output: Contribution to journalArticle

Zaja, F, Bacigalupo, A, Patriarca, F, Stanzani, M, Van Lint, MT, Filì, C, Scimè, R, Milone, G, Falda, M, Vener, C, Laszlo, D, Alessandrino, PE, Narni, F, Sica, S, Olivieri, A, Sperotto, A, Bosi, A, Bonifazi, F & Fanin, R 2007, 'Treatment of refractory chronic GVHD with rituximab: A GITMO study', Bone Marrow Transplantation, vol. 40, no. 3, pp. 273-277. https://doi.org/10.1038/sj.bmt.1705725
Zaja, F. ; Bacigalupo, A. ; Patriarca, F. ; Stanzani, M. ; Van Lint, M. T. ; Filì, C. ; Scimè, R. ; Milone, G. ; Falda, M. ; Vener, C. ; Laszlo, D. ; Alessandrino, P. E. ; Narni, F. ; Sica, S. ; Olivieri, A. ; Sperotto, A. ; Bosi, A. ; Bonifazi, F. ; Fanin, R. / Treatment of refractory chronic GVHD with rituximab : A GITMO study. In: Bone Marrow Transplantation. 2007 ; Vol. 40, No. 3. pp. 273-277.
@article{e9e87cb7f74b4205849dc8908d8d7de0,
title = "Treatment of refractory chronic GVHD with rituximab: A GITMO study",
abstract = "The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to ≥6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65{\%}: skin 17/20 (63{\%}), mouth 10/21 (48{\%}), eyes 6/14 (43{\%}), liver 3/12 (25{\%}), lung 3/8 (37.5{\%}), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n = 3), disease relapse (n = 1), infection (n = 3), sudden death (n = 1). The actuarial 2 year survival is currently 76{\%}. We confirm that Rituximab is effective in over 50{\%} of patients with refractory cGVHD and may have a beneficial impact on survival.",
author = "F. Zaja and A. Bacigalupo and F. Patriarca and M. Stanzani and {Van Lint}, {M. T.} and C. Fil{\`i} and R. Scim{\`e} and G. Milone and M. Falda and C. Vener and D. Laszlo and Alessandrino, {P. E.} and F. Narni and S. Sica and A. Olivieri and A. Sperotto and A. Bosi and F. Bonifazi and R. Fanin",
year = "2007",
month = "8",
doi = "10.1038/sj.bmt.1705725",
language = "English",
volume = "40",
pages = "273--277",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Treatment of refractory chronic GVHD with rituximab

T2 - A GITMO study

AU - Zaja, F.

AU - Bacigalupo, A.

AU - Patriarca, F.

AU - Stanzani, M.

AU - Van Lint, M. T.

AU - Filì, C.

AU - Scimè, R.

AU - Milone, G.

AU - Falda, M.

AU - Vener, C.

AU - Laszlo, D.

AU - Alessandrino, P. E.

AU - Narni, F.

AU - Sica, S.

AU - Olivieri, A.

AU - Sperotto, A.

AU - Bosi, A.

AU - Bonifazi, F.

AU - Fanin, R.

PY - 2007/8

Y1 - 2007/8

N2 - The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to ≥6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes 6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n = 3), disease relapse (n = 1), infection (n = 3), sudden death (n = 1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.

AB - The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to ≥6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes 6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n = 3), disease relapse (n = 1), infection (n = 3), sudden death (n = 1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.

UR - http://www.scopus.com/inward/record.url?scp=34547185482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547185482&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705725

DO - 10.1038/sj.bmt.1705725

M3 - Article

C2 - 17549053

AN - SCOPUS:34547185482

VL - 40

SP - 273

EP - 277

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -